Genmab — Januar 2014
-
concordis?
-
jeg kan ikke finde noget?
-
ADC Therapeutics?
-
-
som min bedre halvdel sagde til mig i går - du skal ikke røre min pad!
-
er der noget der er børsnoteret?
-
-
men lad os lige holde fast i en ting - i modsætning til meditors salg tilbage i april/maj måned, så er det her et offensivt move, der peger frem
-
Therapeutic Application
ADCs have extensive potential therapeutic applications in different disease areas, particularly in cancer. This is evidenced by the publication of promising efficacy data by several pharmaceutical companies including Genentech, and the recent FDA approval of a novel anti-cancer ADC, Seattle Genetics’ Adcetris for the treatment of lymphomas.A number of pharma deals further demonstrate the increased interest in ADCs as next-generation drug candidates for the treatment of
-
of lymphomas.
A number of pharma deals further demonstrate the increased interest in ADCs as next-generation drug candidates for the treatment of cancer including collaborations between Genentech and Seattle Genetics for U.S.$ 910 million, Novartis and Immunogen for U.S.$ 225 million, Pfizer and Seattle Genetics for U.S. $200 million, and Abbott and Seattle Genetics for U.S.$ 200 million.
-
så bliver jeg jo nødt til at afsløre mit alter ego som FF
-
jeg takker af - vi får se i morgen
-
og tak til dig - god aften
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind